KEY FEATURES 

Therapeutic Class: GLP‑1 receptor agonist (peptide therapy)

Primary Uses: Type 2 diabetes management, chronic weight management

Mechanism of Action :

Stimulates insulin secretion when glucose is elevated

Reduces glucagon release 

Slows gastric emptying → appetite suppression

Clinical Benefits :

Proven HbA1c reduction

 Average 10-15% weight loss during trial 

Cardiovascular protection (reduced risk of heart attack/stroke in diabetic patients)

TECHNICAL SPECIFICATIONS 

Molecular Type: Synthetic peptide (semaglutide)

Dosage forms :

Injection pens: 0.25 mg, 0.5 mg, 1 mg, 2 mg (weekly dosing)

Oral tablets: 3 mg, 7 mg, 14 mg (daily dosing)

Brands/Models:

Ozempic® – Weekly injection pen for type 2 diabetes

Wegovy® – Weekly injection pen for weight management

Rybelsus® – Daily oral tablet for type 2 diabetes

Storage & Handling :

Injection pens: Refrigerate until first use; room temperature up to 56 days after opening

Tablets: Store at room temperature, away from moisture

Safety profile :

Common side effects: Nausea, diarrhea, constipation

Serious risks: Pancreatitis, gallbladder issues, kidney problems, rare thyroid tumors

Contraindications: Type 1 diabetes, pregnancy, breastfeeding, history of medullary thyroid carcinoma or MEN2

AVAILABLE CONFIGURATIONS 

Format and Delivery :

Prefilled injection pens (fixed strengths)

Oral tablets (daily dosing)

Compounded vials (for specialized clinical supply)

Concerntration & Dosing:

Branded pens: fixed strengths (0.25–2 mg)

Oral tablets: fixed strengths (3–14 mg)

Custom compounding: adjustable concentrations for research or clinical customization

Packaging & Lebeling:

Bulk API shipments

Finished product packaging (retail-ready)

Private labeling / white‑label options for distributors

Shipping and Compliance :

Cold chain logistics available

Flexible Incoterms (FOB, CIF, DAP, DDP)

Documentation tailored to HS code classification and regulatory requirements